Technical Analysis for PMN - ProMIS Neurosciences Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.00 | 0.73% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Low | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.73% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.73% | |
| NR7 | Range Contraction | 0.73% | |
| Narrow Range Bar | Range Contraction | 0.73% | |
| Inside Day | Range Contraction | 0.73% | |
| Oversold Stochastic | Weakness | 0.73% | |
| 20 DMA Resistance | Bearish | -2.24% | |
| MACD Bullish Signal Line Cross | Bullish | -2.24% |
| Alert | Time |
|---|---|
| Down 5% | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Down 3% | about 17 hours ago |
| 10 DMA Resistance | about 21 hours ago |
| Rose Above 10 DMA | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/12/2024
ProMIS Neurosciences Inc. Description
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Disease Alzheimer's Disease Parkinson's Disease Neurological Disorders Neurodegenerative Diseases Dementia Amyotrophic Lateral Sclerosis Lewy Body Dementia Neurodegenerative Disease Treatment Of Neurodegenerative Diseases Multiple System Atrophy Neuropathology Alpha Synuclein
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.1 |
| 52 Week Low | 0.91 |
| Average Volume | 73,080 |
| 200-Day Moving Average | 1.62 |
| 50-Day Moving Average | 1.10 |
| 20-Day Moving Average | 1.04 |
| 10-Day Moving Average | 1.00 |
| Average True Range | 0.10 |
| RSI (14) | 45.36 |
| ADX | 28.43 |
| +DI | 17.44 |
| -DI | 16.57 |
| Chandelier Exit (Long, 3 ATRs) | 1.26 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.18 |
| Lower Bollinger Band | 0.90 |
| Percent B (%b) | 0.36 |
| BandWidth | 27.13 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0007 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.15 | ||||
| Resistance 3 (R3) | 1.13 | 1.07 | 1.12 | ||
| Resistance 2 (R2) | 1.07 | 1.03 | 1.08 | 1.11 | |
| Resistance 1 (R1) | 1.03 | 1.01 | 1.05 | 1.05 | 1.11 |
| Pivot Point | 0.97 | 0.97 | 0.98 | 0.98 | 0.97 |
| Support 1 (S1) | 0.93 | 0.93 | 0.95 | 0.95 | 0.89 |
| Support 2 (S2) | 0.87 | 0.91 | 0.88 | 0.88 | |
| Support 3 (S3) | 0.83 | 0.87 | 0.87 | ||
| Support 4 (S4) | 0.85 |
